PMID- 31752695
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 19
IP  - 1
DP  - 2019 Nov 21
TI  - Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in 
      patients with inflammatory bowel disease in special situations: a multicentre 
      cohort study.
PG  - 196
LID - 10.1186/s12876-019-1110-1 [doi]
LID - 196
AB  - BACKGROUND: The available information on granulocyte and monocyte adsorptive 
      apheresis (GMA) in patients with inflammatory bowel disease (IBD) under special 
      situations remains unclear. We conducted a retrospective, multicentre cohort 
      study to evaluate the safety and effectiveness of GMA in patients with IBD under 
      special situations. METHODS: This study included patients with ulcerative colitis 
      (UC) or Crohn's disease who had at least one special situation feature and who 
      had received GMA between November 2013 and March 2017. The incidence of adverse 
      events (AEs) was compared in relation to the special situation, and patient 
      background factors related to an AE were identified. For patients with UC, 
      clinical remission was defined as a partial Mayo score of </=2. RESULTS: A total of 
      437 patients were included in this study. The incidence of AEs among the elderly 
      patients (11.2%) was similar in all patients (11.4%), whereas the incidences of 
      AEs in patients on multiple immunosuppressant medications (15.2%), patients with 
      anaemia (18.1%) and paediatric/adolescent patients (18.9%) were higher than that 
      in all patients (11.4%). In multivariate analysis, anaemia and concomitant 
      immunosuppressant medications were independently associated with the incidence of 
      AEs. Clinical remission was achieved in 46.4% of the patients with UC. 
      CONCLUSIONS: The incidence of AEs in the elderly patients was not higher than 
      that in all patients, whereas the incidence of AE was higher in patients with 
      anaemia and those on multiple immunosuppressant medications than that in all 
      patients. GMA is a safe treatment option in elderly patients with IBD.
FAU - Motoya, Satoshi
AU  - Motoya S
AD  - IBD Center, Sapporo Kosei General Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo, 
      Hokkaido, 060-0033, Japan.
FAU - Tanaka, Hiroki
AU  - Tanaka H
AD  - IBD Center, Sapporo Kosei General Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo, 
      Hokkaido, 060-0033, Japan. hirokit@mtc.biglobe.ne.jp.
FAU - Shibuya, Tomoyoshi
AU  - Shibuya T
AD  - Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 
      Hongo, Bunkyo-ku, 113-8431, Tokyo, Japan.
FAU - Osada, Taro
AU  - Osada T
AD  - Department of Gastroenterology, Juntendo University Urayasu Hospital, 2-1-1 
      Tomioka, Urayasu, 279-0021, Chiba, Japan.
FAU - Yamamoto, Takayuki
AU  - Yamamoto T
AD  - Department of Surgery & Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical 
      Center, 10-8 Hazuyamacho, Yokkaichi, 510-0016, Mie, Japan.
FAU - Hongo, Hitoshi
AU  - Hongo H
AD  - Fujita Gastroenterological Hospital, 17-36 Matsubaracho, Takatsuki, 569-0086, 
      Osaka, Japan.
FAU - Mizuno, Chiemi
AU  - Mizuno C
AD  - Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 
      Kawazonocho, Suita, 564-0013, Osaka, Japan.
FAU - Saito, Daisuke
AU  - Saito D
AD  - The Third Department of Internal Medicine, Kyorin University School of Medicine, 
      6-20-2 Shinkawa, Mitaka, 181-8611, Tokyo, Japan.
FAU - Aoyama, Nobuo
AU  - Aoyama N
AD  - Gastrointestinal Endoscopy and IBD Center, Aoyama Medical Clinic, 3-3-19 
      Tamondori, Chuo-ku, Kobe, 650-0015, Hyogo, Japan.
FAU - Kobayashi, Toshihisa
AU  - Kobayashi T
AD  - Department of Gastroenterology, Hakodate Goryoukaku Hospital, 38-3 Goryokakucho, 
      Hakodate, 040-8611, Hokkaido, Japan.
FAU - Ito, Hiroaki
AU  - Ito H
AD  - Kinshukai Infusion Clinic, 3-1 Ofukacho, Kita-ku, Osaka, 530-0011, Osaka, Japan.
FAU - Tanida, Satoshi
AU  - Tanida S
AD  - Department of Gastroenterology and Metabolism, Nagoya City University Graduate 
      School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, 
      Aichi, Japan.
FAU - Nojima, Masanori
AU  - Nojima M
AD  - Center for Translational Research, The Institute of Medical Science Hospital, The 
      University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan.
FAU - Kokuma, Seiichiro
AU  - Kokuma S
AD  - Medical affairs, JIMRO Co., Ltd, 351-1 Nishiyokote, Takasaki, 370-0021, Japan.
FAU - Hosoi, Eiji
AU  - Hosoi E
AD  - Medical affairs, JIMRO Co., Ltd, 351-1 Nishiyokote, Takasaki, 370-0021, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20191121
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Age Factors
MH  - Anemia/complications
MH  - Blood Component Removal/*adverse effects/*methods
MH  - Colitis, Ulcerative/drug therapy/*therapy
MH  - Crohn Disease/drug therapy/*therapy
MH  - Granulocytes
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Monocytes
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC6873503
OTO - NOTNLM
OT  - Anaemia
OT  - Crohn's disease
OT  - Elderly patient
OT  - GMA
OT  - Granulocyte and monocyte adsorptive apheresis
OT  - Immunosuppressant
OT  - Inflammatory bowel disease
OT  - Paediatric patient
OT  - Special situation
OT  - Ulcerative colitis
COIS- SM received consultancy fees from AbbVie G.K., Janssen Pharmaceutical K.K., 
      Kyorin Pharmaceutical, Pfizer Japan Inc. and Takeda Pharmaceutical Co., Ltd.; 
      lecture fees from AbbVie G.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe 
      Pharma Corporation and Mochida Pharmaceutical Co., Ltd. and research grants from 
      EA Pharma Co., Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd. 
      and Pfizer Japan Inc. HT received lecture fees from JIMRO Co., Ltd., AbbVie G.K., 
      EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical and 
      Mitsubishi Tanabe Pharma Corporation. TS and TO received research grants from 
      JIMRO Co., Ltd. DS received research grants from JIMRO Co., Ltd. ST received 
      research grants from EA Pharma Co., Ltd. MN served as a consultant for JIMRO Co., 
      Ltd. SK and EH are personnel of JIMRO Co., Ltd.
EDAT- 2019/11/23 06:00
MHDA- 2020/04/17 06:00
PMCR- 2019/11/21
CRDT- 2019/11/23 06:00
PHST- 2019/03/01 00:00 [received]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/11/23 06:00 [entrez]
PHST- 2019/11/23 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/11/21 00:00 [pmc-release]
AID - 10.1186/s12876-019-1110-1 [pii]
AID - 1110 [pii]
AID - 10.1186/s12876-019-1110-1 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2019 Nov 21;19(1):196. doi: 10.1186/s12876-019-1110-1.